Renovite – regenerative nanoclay for orthobiologic applications

肌肉骨骼疾病是全世界导致残疾的主要因素，最常见和最致残的疾病包括关节炎、背部和颈部疼痛、骨折和受伤。英国目前每年在骨折方面的支出超过20亿GB，随着英国人口老龄化，这一成本将会增加，预计到2030年，英国将有23%的人口年龄在65岁以上。在大约10%的病例中，由于愈合不充分，许多骨折会导致骨科手术需要重复进行。虽然肌肉骨骼疾病的患病率随着年龄的增长而增加，但年轻人也会受到影响，通常是在他们收入最高的年份。目前的骨修复药物在刺激新骨生长方面非常有效，但依赖于非常高的剂量，这与一些危险的副作用有关，如骨骼外过度生长、炎症，有时在脊柱使用时还会损伤神经。一个重要的限制因素是目前无法将骨剂本地化关闭骨骼修复站点，以及其成本。创新英国的资金使Renovos，一家2017年从南安普顿大学剥离出来的年轻整形外科再生医学公司，将该大学的翻译肌肉骨骼研究转化为一种令人兴奋的创新产品，使骨修复剂能够以更精确、更本地化的方式使用，增加了它们的安全性。这一新产品Renovite(R)基于一种合成纳米粘土生物材料，允许以低得多的剂量使用治疗剂以达到同样的效果。此外，由于这些药物只在与细胞接触时释放，它们可以以更有针对性的方式促进愈合，以更高的安全性和更低的成本改善临床结果。有了这项创新英国的资金，Renovos将加快Renovite(R)作为治疗药物的开发，方法是在产品进入首次人体试验之前，在临床前概念验证模型中创建监管机构所需的进一步数据。最终，我们预计我们的新产品将为骨融合手术和难以治疗的骨折提供一种新的组织再生解决方案，为英国经济、需要组织再生的日益活跃的年轻人口以及老龄化的人口提供一系列好处。

Musculoskeletal conditions are the leading contributor to disability worldwide, with the most common and disabling conditions such as arthritis, back and neck pain, fractures and injuries. The UK currently spends over £2 bn/year on bone fractures and this cost is set to increase as the UK population ages and by 2030, it is expected that 23% of the UK population will be aged over 65\. Many bone fractures lead to orthopaedic operations that need to be repeated due to inadequate healing in approximately 10% of cases. While the prevalence of musculoskeletal conditions increases with age, younger people are also affected, often during their peak income-earning years.Current bone healing agents are very effective at stimulating new bone growth, but rely on very high doses which have been associated with some dangerous side effects such as excess bone growth outside of the skeleton, inflammation and sometimes nerve damage when used in the spine. An important limiting factor is the current inability to localise the bone agent close the site of bone repair, and its cost.Innovate UK funding has allowed Renovos, a young orthopaedic regenerative medicine company, spun out from the University of Southampton in 2017, to convert translational musculoskeletal research at the University into an exciting, innovative product, enabling the use of bone-healing agents in a more precise, localised manner, increasing their safety. This novel product, Renovite(r), based on a synthetic nanoclay biomaterial, allows use of the therapeutic agents at much lower doses for the same effect. Furthermore, because these agents are only released upon contact with cells, they can enhance healing in a more targeted manner to improve clinical outcomes with greater safety and at a lower cost.With this Innovate UK funding, Renovos will accelerate development of Renovite(r) as a therapeutic by creating further data required by the regulators in pre-clinical proof-of-concept models before the product can progress into first in-man trials. Ultimately, we anticipate our new product will provide a novel solution for tissue regeneration for bone fusion procedures and difficult-to-treat fractures, providing a range of benefits to the UK economy and for increasingly active, younger demographics requiring tissue regeneration, as well as an ageing population.